We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exosome Diagnostics, Amgen Collaborate
News

Exosome Diagnostics, Amgen Collaborate

Exosome Diagnostics, Amgen Collaborate
News

Exosome Diagnostics, Amgen Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exosome Diagnostics, Amgen Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Exosome Diagnostics Inc has entered into an agreement with Amgen to evaluate the potential to advance drug development with Exosome’s proprietary liquid biopsy diagnostics technology and platform. Under the terms of the agreement, the companies will collaborate to identify a potential liquid biopsy diagnostic. Financial terms of the agreement were not disclosed.

Liquid biopsies are effective in advancing therapeutics because of their distinct advantage over tissue biopsies. A significant advantage is that they are less invasive, resulting in fewer complications and risks to the patient during sample collection. Liquid biopsies enable easier sample collection and may help facilitate patient enrollment into trials.

“We are excited to initiate this agreement with Amgen on developing technology that may advance the use of liquid biopsy tests in clinical development,” stated Mario Morken, Head of Business Development for Exosome Diagnostics. “Exosome Diagnostic’s technology and expertise allows for the development of highly sensitive liquid biopsy assays.”

“The strategy and positioning of the company since the beginning of 2016 is garnering significant results, and we look forward to expounding upon these successes,” stated John Boyce, President and CEO of Exosome Diagnostics.

Advertisement